IC Value
About Us
Editorial Board
Contact Us

Role of anti-leukotriens antagonist, montelukast in bronchial asthma

Authors: Chaudhury Alisha. Gaude Gajanan S, Hattiholi Jyothi
Int J Biol Med Res. 2015; 6(1): 4685-4689  |  PDF File


Asthma is one of the most common chronic diseases globally with a rising incidence in developing countries. Asthma severity is now classified on the basis of the intensity of treatment required to achieve good asthma control. The standard treatment of bronchial asthma depends on the stage of the disease and usually consists of combination of inhaled steroids and long acting beta 2 agonists. Leukotriene receptor antagonists (LTRAs) are a class of drugs which specifically act on leukotriene receptors and they have an established role in the management of chronic asthma. They may also provide benefit, additional to that achieved by current treatment, in acute attack. They have been shown to have acute bronchodilator effect which may be of additional help in acute attack of bronchial asthma. Here we have reviewed the clinical efficacy of anti-leukotriene antagonist, Montelukast in the management of bronchial asthma.